Bio-Rad Laboratories has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug or the complex of the drug with its target, vascular endothelial growth factor A (VEGF-A). Read more


Genentech has unveiled positive results from its Phase II LADDER study, which evaluated the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD). Read more


A co-development agreement has been formed by Xbrane Biopharma and STADA Arzeneimittel for the development of Xlucane — a biosimilar to Lucentis (ranibizumab), which is mainly used for the treatment of wet age-related macular degeneration (AMD). Read more


The US FDA has approved Genetech’s Lucentis (ranibizumab injection) 0.3 mg prefilled syringe as a new administration method for the treatment of all forms of diabetic retinopathy (DR) in patients with diabetic macular oedema Read more